

Product Datasheet

SARS-CoV-2 (COVID-19) Nucleocapsid Antibody (orb1239972)

Description	SARS-CoV-2 (COVID-19) Nucleocapsid Antibody
Species/Host	Rabbit
Reactivity	Virus
Conjugation	Unconjugated
Tested Applications	ELISA, WB
Immunogen	Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody (orb1239972) was raised against a peptide corresponding to 17 amino acids near the center of SARS-CoV-2 (COVID-19) Nucleocapsid protein. The immunogen is located within 230-280 amino acids of SARS-CoV-2 (COVID-19) Nucleocapsid protein.
Target	N
Preservatives	SARS-CoV-2 (COVID-19) Nucleocapsid Antibody is supplied in PBS containing 0.02% sodium azide.
Form/Appearance	Liquid
Concentration	1 mg/mL
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Note	For research use only
Isotype	IgG
Clonality	Polyclonal
NCBI	QHD43423


Biorbyt Ltd.

7 Signet Court, Swann's Road,
Cambridge, CB5 8LA, United Kingdom
Email: info@biorbyt.com, support@biorbyt.com
Phone: [+44 \(0\) 1223 859-353](tel:+44(0)1223859353) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)


Biorbyt LLC.

68 TW Alexander Drive,
Durham, NC, 27713, United States
Email: info@biorbyt.com, support@biorbyt.com
Phone: [+1 \(415\) 906-5211](tel:+1(415)9065211) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)


Expiration Date 12 months from date of receipt.



Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient (Sun et al., 2020). Detection of SARS-CoV-2 nucleocapsid protein by anti-SARS-COV-2 nucleocapsid antibodies (orb1239972, 0.02 $\mu\text{g}/\text{mL}$, A



B) or SARS-CoV-2 Spike S1 antibodies (orb1239995, 1 $\mu\text{g}/\text{mL}$ D




E) in adjacent sections of autopsy lung tissue from COVID-19 deceased patient. Negative control staining on autopsy lung tissue from patient who died from non-COVID-19 pneumonia is shown for Nucleocapsid protein (C) or Spike protein (F). Negative control using normal rabbit immunoglobulin on COVID-19 autopsy tissue is presented (G). DAB chromogen and hematoxylin counterstain are used. Scale bars: 50 μM in A, C, D, F, G; 20 μM in B and E.

Biorbyt Ltd.


7 Signet Court, Swann's Road,
Cambridge, CB5 8LA, United Kingdom
Email: info@biorbyt.com, support@biorbyt.com
Phone: [+44 \(0\) 1223 859-353](tel:+44(0)1223859353) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)

Biorbyt LLC.


68 TW Alexander Drive,
Durham, NC, 27713, United States
Email: info@biorbyt.com, support@biorbyt.com
Phone: [+1 \(415\) 906-5211](tel:+1(415)9065211) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)



Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient. Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody (orb1239972, 0.02 µg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 °C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Dr. Hallgeir Rui, MCW) (Picture shown in 40X magnification).



Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient. Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody (orb1239972, 0.02 µg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 °C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Dr. Hallgeir Rui, MCW) (Picture shown in 63X magnification).



Western Blot Validation with SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein. Loading: 50 ng per lane of SARS-CoV-2 (COVID-19) Nucleocapsid recombinant protein. Antibodies: SARS-CoV-2 (COVID-19) Nucleocapsid, orb1239972, 1 h incubation at RT in 5% NFD/MTBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 0.5 µg/mL, Lane 2: 1 µg/mL and Lane 3: 2 µg/mL.

Biorbyt Ltd.

7 Signet Court, Swann's Road,
Cambridge, CB5 8LA, United Kingdom
Email: info@biorbyt.com, support@biorbyt.com
Phone: [+44 \(0\) 1223 859-353](tel:+44(0)1223859353) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)

Biorbyt LLC.

68 TW Alexander Drive,
Durham, NC, 27713, United States
Email: info@biorbyt.com, support@biorbyt.com
Phone: [+1 \(415\) 906-5211](tel:+1(415)9065211) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)